• Ed Silverman
• 15 Jan, 2019

one of the many proposals the Trump administration is kicking around in order to lower drug costs would shift coverage of some medicines from Medicare Part B to Part D, which is administered by privately managed care plans. A new analysis, however, cautions that while government spending might be reduced, the proposal may also increase out-of-pocket costs for some beneficiaries.
Read more...